Ocular Gene Therapy for Horses with Uveitis
Author Information
Author(s): Young Kim, Hasegawa Tomoko, Vridhachalam Naveen, Henderson Nichol, Salmon Jacklyn H., McCall Trace F., Hirsch Matthew L., Gilger Brian C.
Primary Institution: North Carolina State University
Hypothesis
The study hypothesized that intravitreal AAV8-eqIL-10 would be well tolerated in a dose-dependent manner in horses.
Conclusion
The study found that AAV8-eqIL-10 injections were well tolerated in horses, with mild transient ocular inflammation but no systemic effects.
Supporting Evidence
- AAV8-eqIL-10 injections resulted in high concentrations of eqIL-10 in the aqueous and vitreous humor.
- Mild ocular inflammation was observed, particularly in horses receiving the highest dose.
- No vector genomes were detected in urine or feces at any time.
- Transient ocular inflammation resolved within a week in most cases.
- Systemic distribution of vector genomes was limited to the liver and kidney.
Takeaway
Researchers tested a new eye treatment for horses that helps with a painful eye disease, and it worked well without causing serious problems.
Methodology
Five horses received intravitreal injections of either a saline control, a low dose, or a high dose of AAV8-eqIL-10, followed by clinical examinations and sample collections over 86 days.
Potential Biases
The horses were donated, which may introduce selection bias.
Limitations
The study had a small sample size and a sex bias towards female horses.
Participant Demographics
Horses ranged in age from 11 to 22 years, consisting of four females and one male, representing three breeds: Thoroughbreds, Quarter Horses, and ponies.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website